Pharmacokinetic and Pharmacodynamic Action of Etodolac in Patients after Oral Surgery

Journal of Clinical Pharmacology

Volumn 39, Issue 7, 1999, Pages 729-737

  Boni, Joseph ^a,c   Korth Bradley, Joan ^a   McGoldrick, Karen ^a   Appel, Alan ^a   Cooper, Stephen ^b  

^a WYETH AYERST RESEARCH   (United States)

^b PFIZER INC   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETODOLAC; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; METABOLIC CLEARANCE RATE; ORAL SURGERY; PAIN; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TIME;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETODOLAC; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PAIN; PAIN MEASUREMENT; SURGERY, ORAL; TIME FACTORS;

EID: 0033160576     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922008254     Document Type: Article

References (25)

1. Dey M, Enever R, Marino M, Michelucci J, Smith D, Warner R, et al: Sustained-release etodolac bioavailability and dose proportionality: correlation between in vivo and in vitro performance, Int J Pharmaceut 1989;49:121-128.
2. Brocks DR, Jamali F: Etodolac clinical pharmacokinetics. Clin Pharmacokinet 1994;26:259-274.
3. Benet LZ: Pharmacokinetics of sustained-release etodolac. Rheumatol Int 1993;13:S3-S5.
4. Ferdinandi ES, Sehgal SN, Demerson CA, Dubuc J, Zilber J, Dvornik D, et al: Disposition and biotransformation of 14C-etodolac in man. Xenobiotica 1986;16:153-166.
5. Cayen MN, Kraml M, Ferdinandi ES, Greselin E, Dvornik D: The metabolic disposition of etodolac in rats, dogs, and man. Drug Metab Rev 1981;12:339-362.
6. Tucker PW, Smith JR, Adams DF: A comparison of 2 analgesic regimens for the control of postoperative periodontal discomfort. J Periodontol 1996;67(2):125-129.
7. Giglio JA, Campbell RL: Comparison of etodolac, zomepirac, and placebo for relief of pain after oral surgery. J Oral Maxillofac Surg 1986;44(10):765-770.
8. Fliedner L, Levsky M, Kechjian H, Berger J, Gaston G, et al: Analgesia with etodolac in oral postsurgical pain. Curr Ther Res 1983;33:100-107.
9. Gaston GW, Mallow RD, Frank JE: The efficacy of etodolac for patients with pain following oral surgery. J Oral Maxillofac Surg 1984;42:562-366.
10. Nelson SL, Bergman SA: Relief of dental surgery pain: a controlled 12-hour comparison of etodolac, aspirin, and placebo. Anesthesia Prog 1985;32(4):151-156.
11. Casey R, Zadra J, Khonsari H: A comparison of etodolac (Ultradol) with acetaminophen plus codeine (Tylenol:3) in controlling post-surgical pain in vasectomy patients. Curr Med Res Opin 1997;13(10): 555-563. (published erratum appears in Curr Med Res Opin 1997;14(1):63)
12. Max M, LaskaE: Single-dose analgesic comparisons. In, Max MB, Portenoy R, Laska E (eds.): Advances in Pain Research and Therapy. New York: Raven, 1991;55-65.
13. Cosyns L, Spain M, Kraml M: Sensitive high-performance liquid Chromatographic method for the determination of etodolac in serum. J Pharm Sci 1983;72(3):275-277.
14. SAS Institute: SAS/STAT User's Guide. 4th ed. Cary, NC: SAS Institute, 1990.
15. Beal SL, Sheiner LB (eds.): NONMEM User's Guide. San Francisco: University of California at San Francisco, 1992.
16. Dayneka NL, Garg V, Jusko WJ: Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993;21(4):457-478.
17. Glaser KB, Sung A: Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PHHS-2) versus human PHGS-1. Eur J Pharmacol 1995;281:107-111.
18. Metzler CM, Weiner DL: PCNONLIN (version 4.0). Lexington, KY: Statistical Consultants Software, 1992.
19. Levin L: Extended-release etodolac in post-surgical dental pain. J Oral Maxillofac Surg 1997;55(8, Suppl. 3):57.
20. Inturrisi CE, Colburn WA, Kaiko RF, et al: Pharmacokinetic and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987;41:392-401.
21. Inturrisi CE, Portenoy RK, Max MB, et al: Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. Clin Pharmacol Ther 1990;47:565-577.
22. Chiang ST, Ermer JC, Osman M, et al: Pharmacokinetic-pharmacodynamic relationships of bromfenac in mice and humans. Pharmacotherapy 1996;16:1179-1187.
23. Mandema JW, Stanski DR: Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996;60:619-635.
24. Sheiner LB, Beal SL, Dunne A: Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials. J Amer Stat Assoc 1997;92:1235-1244.
25. Suri A, Grundy BL, Derendorf H: Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. InI J Clin Pharmacol 1997;35:1-8.